Dementia research news

The latest in dementia treatment and diagnosis

Learn more about the biggest advancements to date in the development of dementia drugs and treatments as well as news relating to improving dementia diagnosis.

Researching new drugs for Alzheimer’s disease

For the first time, drugs that slow down memory and thinking decline in early Alzheimer’s disease have been approved by UK regulators. But research never stops. Here we explore the next wave of promising new drugs.

Blood biomarkers for diagnosis

Blood-based biomarkers could be the cost-effective, accurate and non-invasive diagnostic tool that is needed to revolutionise diagnosis.

Alzheimer's drug Lecanemab approved for use in the UK, but not on the NHS

Today (Thursday 22 August), the MHRA and NICE have made announcements on lecanemab, a ground-breaking new treatment for Alzheimer’s disease.

New Alzheimer's drug: donanemab

Donanemab could slow down memory and thinking decline in people living with early-stage Alzheimer’s disease. Here's what we know so far about this Alzheimer's drug.

New Alzheimer's drug: lecanemab

Lecanemab offers promise as a new drug for people living with early-stage Alzheimer’s disease. Here is what we know so far about this breakthrough Alzheimer's drug.

2024: An exciting year for dementia research

With announcements about new drugs for Alzheimer's due 2024, it could be the biggest year for dementia research yet! On top of that we're running a number of projects and supporting new research.

Opinions from our experts

Read the latest insights and opinions of Alzheimer's Society experts.

How do we ensure Early Career Researchers stay in dementia research?

Fiona Carragher, Director of Research and Influencing at Alzheimer's Society, discusses what needs to be done to ensure the next generation of dementia leaders is supported and thrives in their field.

Dementia breakthrough drugs could be a golden opportunity – we need to seize it

In light of the latest news on donanemab, Richard Oakley, Associate Director of Research and Innovation at Alzheimer's Society, discusses the future of dementia diagnosis.

Alzheimer's Society stresses importance of diagnosis in response to new Panorama documentary

Fiona Carragher responds to a new BBC Panaroma documentary which focuses on new drugs that may change the future of Alzheimer's disease treatment.

Dementia research updates

Learn about the most recent news in the wider dementia research community.

Alzheimer’s Society responds to EU’s rejection of lecanemab

Today (26 July), the European Union’s drugs regulator, the Committee for Medicinal Products for Human Use (CHMP), has advised that the drug lecanemab, a treatment for Alzheimer’s disease, should not be approved for use in the EU.

Alzheimer's Society respond to FDA decision on Alzheimer's drug lecanemab

The Food and Drug Administration has today approved lecanemab, a new drug for Alzheimer's disease, for use across the US.

New drug donanemab is 'a turning point in the fight against Alzheimer’s'

Dr Richard Oakley, Associate Director of Research at Alzheimer’s Society, has called breakthrough Alzheimer's drug donanemab, 'a turning point', as the full trial results were revealed.

Alzheimer's Society research updates

Read the latest about dementia research conducted and funded by Alzheimer's Society.

Two new dementia risk factors identified in Lancet Commission study

The updated Lancet Commission study, which was part funded by Alzheimer's Society, has identified two new risk factors for dementia: untreated vision loss and high low-density lipoprotein (LDL)/bad cholesterol. 

UK comes a step closer to blood tests for diagnosing dementia

Two world-class research teams will carry out countrywide trials to identify accurate and quick blood tests that can diagnose dementia, in a bid to improve the UK’s shocking diagnosis rate.